- Home
- GALT vs VANI Comparison
GALT vs VANI Comparison
Compare GALT & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- VANI
- Stock Information
- Founded
- GALT 2000
- VANI 1998
- Country
- GALT United States
- VANI United States
- Employees
- GALT N/A
- VANI 36
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GALT Health Care
- VANI Health Care
- Exchange
- GALT Nasdaq
- VANI Nasdaq
- Market Cap
- GALT 83.5M
- VANI 75.2M
- IPO Year
- GALT N/A
- VANI 2014
- Fundamental
- Price
- GALT $2.52
- VANI $1.40
- Analyst Decision
- GALT Buy
- VANI Strong Buy
- Analyst Count
- GALT 2
- VANI 1
- Target Price
- GALT $6.00
- VANI $4.00
- AVG Volume (30 Days)
- GALT 1.5M
- VANI 134.3K
- Earning Date
- GALT 08-12-2025
- VANI 08-12-2025
- Dividend Yield
- GALT N/A
- VANI N/A
- EPS Growth
- GALT N/A
- VANI N/A
- EPS
- GALT N/A
- VANI N/A
- Revenue
- GALT N/A
- VANI N/A
- Revenue This Year
- GALT N/A
- VANI N/A
- Revenue Next Year
- GALT N/A
- VANI N/A
- P/E Ratio
- GALT N/A
- VANI N/A
- Revenue Growth
- GALT N/A
- VANI N/A
- 52 Week Low
- GALT $0.73
- VANI $0.91
- 52 Week High
- GALT $3.90
- VANI $1.50
- Technical
- Relative Strength Index (RSI)
- GALT 63.30
- VANI 74.26
- Support Level
- GALT $2.07
- VANI $1.26
- Resistance Level
- GALT $2.36
- VANI $1.30
- Average True Range (ATR)
- GALT 0.27
- VANI 0.06
- MACD
- GALT -0.01
- VANI 0.00
- Stochastic Oscillator
- GALT 61.64
- VANI 69.70
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.